Studies with smaller sample sizes
Transforming Drug Development
The Coral Biomarker Discovery Service enables pharmaceutical companies to use genome sequencing with clinical data to develop more precise therapies, at a fraction of the time and cost of traditional methods.
Built on the foundation of Mantis’ highly accurate individual genome interpretation framework, Coral uses a unique set-based approach to identify drug response markers from among the millions of genetic variants in a study population.
Coral delivers answers, even within small sample sizes, reflecting the reality of many Phase II clinical trials. With the ability to look across the entire genome of each patient, Coral opens the door to novel biomarkers and drug targets.